Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2010

01-10-2010 | Original Article

Association between IGF-1 and chronic kidney disease among US adults

Authors: Srinivas Teppala, Anoop Shankar, Charumathi Sabanayagam

Published in: Clinical and Experimental Nephrology | Issue 5/2010

Login to get access

Abstract

Background

Insulin-like growth factor (IGF-1) has been associated with cardiovascular disease, hypertension and diabetes in previous studies. However, the association between IGF-1 and chronic kidney disease (CKD) has not been previously studied. Therefore, we examined the association between serum IGF-1 and CKD in a representative sample of US adults.

Methods

We conducted a cross-sectional study of 5388 Third National Health and Nutrition Examination Survey (NHANES III) participants aged ≥20 years of age (55.2% women). Serum IGF-1 was categorized into quartiles for the analysis. CKD (n = 241) was defined as an estimated glomerular filtration rate of <60 mL/min/1.73/m2.

Results and conclusion

Higher serum IGF-1 levels were positively associated with CKD after adjusting for age, sex, race/ethnicity, education levels, smoking, alcohol intake, body mass index, diabetes, hypertension and serum cholesterol. Compared to quartile 1 of IGF-1 (referent), the odds ratio (95% confidence interval) of CKD associated with quartile 4 was 2.66 (1.18–5.99); p trend = 0.008. Subgroup analysis that examined the relation between IGF-1 and CKD by gender showed a consistent positive association. In summary, increasing levels of serum IGF-1 were positively associated with CKD in a representative sample of US adults. Our results suggest that IGF-1 might be a predictor of CKD in Western populations.
Literature
1.
go back to reference Ferns GA, Motani AS, Anggard EE. The insulin-like growth factors: their putative role in atherogenesis. Artery. 1991;18(4):197–225.PubMed Ferns GA, Motani AS, Anggard EE. The insulin-like growth factors: their putative role in atherogenesis. Artery. 1991;18(4):197–225.PubMed
2.
go back to reference Andreassen M, Raymond I, Kistorp C, Hildebrandt P, Faber J, Kristensen LO. IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol. 2009;160(1):25–31.CrossRefPubMed Andreassen M, Raymond I, Kistorp C, Hildebrandt P, Faber J, Kristensen LO. IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol. 2009;160(1):25–31.CrossRefPubMed
3.
go back to reference Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002;106(8):939–44.CrossRefPubMed Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002;106(8):939–44.CrossRefPubMed
4.
go back to reference Okura Y, Brink M, Zahid AA, Anwar A, Delafontaine P. Decreased expression of insulin-like growth factor-1 and apoptosis of vascular smooth muscle cells in human atherosclerotic plaque. J Mol Cell Cardiol. 2001;33(10):1777–89.CrossRefPubMed Okura Y, Brink M, Zahid AA, Anwar A, Delafontaine P. Decreased expression of insulin-like growth factor-1 and apoptosis of vascular smooth muscle cells in human atherosclerotic plaque. J Mol Cell Cardiol. 2001;33(10):1777–89.CrossRefPubMed
5.
go back to reference Verdecchia P, Reboldi G, Schillaci G, et al. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation. 1999;100(17):1802–7.PubMed Verdecchia P, Reboldi G, Schillaci G, et al. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation. 1999;100(17):1802–7.PubMed
6.
go back to reference Ito H, Hiroe M, Hirata Y, et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation. 1993;87(5):1715–21.PubMed Ito H, Hiroe M, Hirata Y, et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation. 1993;87(5):1715–21.PubMed
7.
go back to reference Decker RS, Cook MG, Behnke-Barclay M, Decker ML. Some growth factors stimulate cultured adult rabbit ventricular myocyte hypertrophy in the absence of mechanical loading. Circ Res. 1995;77(3):544–55.PubMed Decker RS, Cook MG, Behnke-Barclay M, Decker ML. Some growth factors stimulate cultured adult rabbit ventricular myocyte hypertrophy in the absence of mechanical loading. Circ Res. 1995;77(3):544–55.PubMed
8.
go back to reference Yoshida H, Mitarai T, Kitamura M, et al. The effect of selective growth hormone defect in the progression of glomerulosclerosis. Am J Kidney Dis. 1994;23(2):302–12.PubMed Yoshida H, Mitarai T, Kitamura M, et al. The effect of selective growth hormone defect in the progression of glomerulosclerosis. Am J Kidney Dis. 1994;23(2):302–12.PubMed
9.
go back to reference Feld S, Hirschberg R. Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev. 1996;17(5):423–80.PubMed Feld S, Hirschberg R. Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev. 1996;17(5):423–80.PubMed
10.
go back to reference Mehls O, Irzynjec T, Ritz E, et al. Effects of rhGH and rhIGF-1 on renal growth and morphology. Kidney Int. 1993;44(6):1251–8.CrossRefPubMed Mehls O, Irzynjec T, Ritz E, et al. Effects of rhGH and rhIGF-1 on renal growth and morphology. Kidney Int. 1993;44(6):1251–8.CrossRefPubMed
11.
go back to reference Frystyk J, Ivarsen P, Skjaerbaek C, Flyvbjerg A, Pedersen EB, Orskov H. Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int. 1999;56(6):2076–84.CrossRefPubMed Frystyk J, Ivarsen P, Skjaerbaek C, Flyvbjerg A, Pedersen EB, Orskov H. Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int. 1999;56(6):2076–84.CrossRefPubMed
12.
go back to reference Colao A, Di SC, Cascella T, et al. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol. 2008;159(4):389–97.CrossRefPubMed Colao A, Di SC, Cascella T, et al. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol. 2008;159(4):389–97.CrossRefPubMed
17.
go back to reference Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–54.PubMed Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–54.PubMed
18.
go back to reference Eknoyan G, Levin NW. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266. Eknoyan G, Levin NW. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266.
19.
go back to reference Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–52.CrossRefPubMed Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–52.CrossRefPubMed
20.
go back to reference Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16(1):3–34.PubMed Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16(1):3–34.PubMed
21.
go back to reference Abdulle AM, Gillett MP, Abouchacra S, et al. Low IGF-1 levels are associated with cardiovascular risk factors in haemodialysis patients. Mol Cell Biochem. 2007;302(1–2):195–201.CrossRefPubMed Abdulle AM, Gillett MP, Abouchacra S, et al. Low IGF-1 levels are associated with cardiovascular risk factors in haemodialysis patients. Mol Cell Biochem. 2007;302(1–2):195–201.CrossRefPubMed
22.
go back to reference Hirschberg R, Kopple JD. Evidence that insulin-like growth factor I increases renal plasma flow and glomerular filtration rate in fasted rats. J Clin Investig. 1989;83(1):326–30.CrossRefPubMed Hirschberg R, Kopple JD. Evidence that insulin-like growth factor I increases renal plasma flow and glomerular filtration rate in fasted rats. J Clin Investig. 1989;83(1):326–30.CrossRefPubMed
23.
go back to reference Feld SM, Hirschberg R, Artishevsky A, Nast C, Adler SG. Insulin-like growth factor I induces mesangial proliferation and increases mRNA and secretion of collagen. Kidney Int. 1995;48(1):45–51.CrossRefPubMed Feld SM, Hirschberg R, Artishevsky A, Nast C, Adler SG. Insulin-like growth factor I induces mesangial proliferation and increases mRNA and secretion of collagen. Kidney Int. 1995;48(1):45–51.CrossRefPubMed
Metadata
Title
Association between IGF-1 and chronic kidney disease among US adults
Authors
Srinivas Teppala
Anoop Shankar
Charumathi Sabanayagam
Publication date
01-10-2010
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2010
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-010-0307-y

Other articles of this Issue 5/2010

Clinical and Experimental Nephrology 5/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.